WuXi STA completes acquisition of drug product manufacturing facility

The Couvet site is the company’s first facility in Europe

WuXi STA, a subsidiary of WuXi AppTec, has completed the acquisition of a drug product manufacturing facility in Switzerland from Bristol Myers Squibb. The company first announced its plans to purchase the facility earlier this year. The acquisition will enhance its capabilities by adding capacity to support its global partners in bringing innovative medicines to patients around the world.

The Couvet site is the company’s first facility in Europe. Opened in 2018, the facility’s tablet and capsule manufacturing and packaging capabilities will provide customers more flexibility thanks to a larger supply of drug product and greater access to the European market and beyond.

By enhancing its network, WuXi STA says it can better support customers’ long-term needs globally, as they bring commercial manufacturing projects from their pipelines to the facility, with the capability and capacity to supply drug products to global markets.

“We are delighted to have added the Couvet site to our global supply network and are excited to welcome its highly skilled team to the WuXi STA family,” said Dr Minzhang Chen, Co-CEO of WuXi AppTec. “Through combining resources of the Couvet site with our other facilities, we continue strengthening and broadening our capacity and capabilities to better support our global customers in delivering innovative medicines to patients in need.”

Through this transaction, the company has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including the recently announced Middletown site in Delaware, USA.

Companies